

Press Release

ReVivo Medical Receives NIH Grant

ALBANY, NY, October 28, 2015 – ReVivo Medical, LLC, announced today that the National Institutes of Health has awarded the company a grant as part of the Small Business Innovation Research (SBIR) Program. The Phase I award, worth \$225,000, will be administered by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and will be utilized to support the development of ReVivo's flagship product – a cervical spinal fusion plate that improves the efficiency of the surgeon and the long term outcomes of the patient.

"NIH awards are extremely competitive and we are honored to receive it," said Glenn Sanders, ReVivo Medical's Chief Technology Officer, "Being awarded this grant is a recognition from the highest caliber organization in the health care field that our technology is likely to have a large and valuable impact."

"This grant will fund an important step in our product development plan," says Gary Mittleman, president and CEO. "There are 500,000+ patients that receive spinal fusions each year. Our goal is to provide a better product for them."

Glenn Sanders, Ph.D., is a faculty member at Union College, and will be the Principal Investigator on the grant. He will work in close collaboration with Darryl DiRisio, M.D. a preeminent neurosurgeon at Albany Medical Center and Eric H. Ledet, Ph.D. ReVivo Medical's Chief Science Officer and a renowned spine researcher at Rensselaer Polytechnic Institute.

About ReVivo Medical, LLC., headquartered in Albany, New York, is developing elastic micro-motion implantable medical products for use by surgeons on patients with spinal pathology. Spinal surgeries often use plates (akin to splints) to hold the vertebrae in place during the healing process. The founders, Darryl DiRisio, MD. a spinal surgeon at Albany Medical Center and two biomedical engineers: Eric Ledet, PhD. and Glenn Sanders, PhD. teamed up in 2011 with the aim of developing products that improve patient health, facilitate an easier surgery process and reduce costs in this ever competitive healthcare arena. The Company expects its first commercial sales in 2017.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are not purely historical regarding ReVivo Medical's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the development, cost, size, intended use and technical specifications of the medical products, the potential impact on outcomes and costs associated with spinal surgeries, and the potential profits to be made by ReVivo Medical pursuant to the successful commercialization of their product(s) and the size of market and market share of products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from ReVivo Medical's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the inability to successfully develop new products and obtain regulatory approval; a

lack of acceptance in the marketplace by physicians and patients; the inability to manufacture products in commercial quantities at an acceptable cost; possible delays in the company's development programs; the inability of patients or hospitals to receive reimbursement from third-party payors; and inadequate financial and other resources.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to ReVivo Medical, and ReVivo Medical assumes no obligation to update any such forward-looking statement or reasons why results might differ.

Contacts: ReVivo Medical, LLC.

www.revivomedical.com

Gary Mittleman, President and CEO (518) 527-4747 or

Eric Ledet, PhD., Chief Science Officer (518) 928-2455

info@revivomedical.com